![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
An Interferon- and Ribavirin-Free 12-Week Regimen of Once-Daily VX-135 and Daclatasvir in Treatment-Naïve Patients With Genotype 1 HCV Infection
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
E. Gane1, C. Stedman2, V. Garg3, S. George3, T. Kieffer3, J. Krop3, L. Lan3, R. Rubin3, and A. Lawal3
1. Auckland Clinical Studies, Grafton, New Zealand; 2. Christchurch Clinical Studies, Christchurch, New Zealand; 3. Vertex Pharmaceuticals Incorporated, Boston, MA, USA
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C - (01/31/14)
VX-135, A Once-daily Nucleotide HCV Polymerase Inhibitor, Was Well Tolerated And Demonstrated Potent Antiviral Activity When Given With Ribavirin In Treatment-naïve Patients With Genotype 1 HCV......http://www.natap.org/2013/AASLD/AASLD_14.htm
![EASL1.gif](../images/041714/041614-5/EASL1.gif)
![EASL2.gif](../images/041714/041614-5/EASL2.gif)
![EASL3.gif](../images/041714/041614-5/EASL3.gif)
![EASL4.gif](../images/041714/041614-5/EASL4.gif)
![EASL5.gif](../images/041714/041614-5/EASL5.gif)
![EASL6.gif](../images/041714/041614-5/EASL6.gif)
![EASL7.gif](../images/041714/041614-5/EASL7.gif)
![EASL8.gif](../images/041714/041614-5/EASL8.gif)
![EASL9.gif](../images/041714/041614-5/EASL9.gif)
![EASL10.gif](../images/041714/041614-5/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|